Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Holgate

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Idrugs : the Investigational Drugs Journal|April 8, 2009
Circumventing immunogenicity in the development of therapeutic antibodiesRobert G E Holgate, Matthew P Baker
Plos One|September 16, 2015
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced ImmunogenicityRobert G E Holgate, Richard Weldon, Timothy D Jones, et al.
Platelets|October 21, 2005
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responsesHeather M Judge, Robert J Buckland, Carol E Holgate, et al.
Protein Engineering, Design & Selection : PEDS|September 1, 2016
A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warheadTim D Jones, Arron R Hearn, Robert G E Holgate, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Idrugs : the Investigational Drugs Journal|April 8, 2009
Circumventing immunogenicity in the development of therapeutic antibodiesRobert G E Holgate, Matthew P Baker
Plos One|September 16, 2015
Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced ImmunogenicityRobert G E Holgate, Richard Weldon, Timothy D Jones, et al.
Platelets|October 21, 2005
Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responsesHeather M Judge, Robert J Buckland, Carol E Holgate, et al.
Protein Engineering, Design & Selection : PEDS|September 1, 2016
A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warheadTim D Jones, Arron R Hearn, Robert G E Holgate, et al.
Mabs|December 31, 2015
The INNs and outs of antibody nonproprietary namesTim D Jones, Paul J Carter, Andreas Plückthun, et al.
Pageof 1